Structural Characterization, Optical Properties, and Phase Transitions of In 1– x Sn x Alloy Thin Films

Peng

et al. 2023

Front. Mol. Biosci.

Osteosarcoma is the malignant tumor with the highest incidence rate among primary bone tumors and with a high mortality rate. The anti-osteosarcoma materials are the cross field between material science and medicine, having a wide range of application prospects. Among them, biological materials, such as compounds from black phosphorous, magnesium, zinc, copper, silver, etc., becoming highly valued in the biological materials field as well as in orthopedics due to their good biocompatibility, similar mechanical properties with biological bones, good biodegradation effect, and active antibacterial and anti-tumor effects. This article gives a comprehensive review of the research progress of anti-osteosarcoma biomaterials.

Section: Other Bio-materialsmentioning

confidence: 99%

Multifunctional inorganic biomaterials: New weapons targeting osteosarcoma

Peng

et al. 2023

Front. Mol. Biosci.

“…Yang et al 90 prepared B 2 WO 6 -reduced graphene oxide (BWO−RGO) nanocomposites via electrostatic self-assembly of positively charged BWO with negatively charged graphene oxide sheets and applied for the selective reduction of 4-nitrophenol under photocatalytic conditions (Scheme 38 ). The electronic interaction between BWO and RGO helps in the separation of the edges of valence and conduction bands and improved the photogenerated electrons/holes separation to consequently influence the photocatalytic reduction and oxidation reactions, respectively.…”

Section: Photocatalytic Reduction Of Nitro Compounds To Valuable Scaf...mentioning

confidence: 99%

Recent Developments in Photocatalytic Reduction of Nitro Compounds to Valuable Scaffolds

Aggarwal

Bala

Malik

et al. 2023

Synlett

The reduction of nitro compounds is one of the fundamental organic transformations and ascertain wide applicability in industrial chemistry, synthesis of valuable scaffolds, fine chemical synthesis as well as environmental applicability for decontamination process. The transformation involves the conversion of nitro compounds to valuable scaffolds including amino, nitroso, hydroxyl amines, azo and hydrazo compounds. Conventional approaches for the reduction of nitro compounds involves the environmentally harmful stoichiometric reagents, high boiling reaction media, tedious processes, and harsh reaction conditions with high temperature and pressure. Additionally, the selectivity always remains a serious concern associated with the process due to the possibilities of several stable intermediate formation in the reaction pathway of reduction of nitro compounds. Nitro compounds are also of serious environmental concerns being a part of most harmful and high-priority classes of pollutants mainly released from industrial effluents, agricultural waste, and human sewage. A simple degradation of these pollutants bearing nitro group just removes the pollutants, however, the selective reduction of nitro group to valuable functionalities as mentioned above provides the industrially important scaffolds. Herein, the present review article is focused on the recent developments in the photocatalytic reduction of nitro compounds to valuable scaffolds.

“…The comprehensive understanding of oncology and the interdisciplinary advances covering medicine, biology, engineering, nanobiotechnology, etc., [ 27–31 ] strengthen our confidence to develop desirable multifaceted nanomodulators to address various limiting factors against ROS production and therapy and cater to the increasing clinical demands. In this report, a multichannel sonocatalysis amplifier has been established via the one‐pot synthesis of triptolide (TPL) and IR780 co‐loaded CaCO 3 nanoparticles modified with DSPE‐mPEG (IR780/TPL@Ca‐SA), which can promote oxidative stress deposition and boost the tumor vulnerability to ROS therapy.…”

Section: Introductionmentioning

confidence: 99%

Multichannel Sonocatalysis Amplifiers Target IDH1‐Mutated Tumor Plasticity and Attenuate Ros Tolerance to Repress Malignant Cholangiocarcinoma

Zhu

et al. 2023

Adv Funct Materials

Tumor adaptation‐originated tumor tolerance that compensatory mechanisms (e.g., isocitrate dehydrogenase (IDH) mutation) jointly shape is the dominant obstacle of ROS therapy. Currently, targeting a single pathway fails to fundamentally reverse the complex milieu and diminish tumor adaptation. Herein, a multichannel sonocatalysis amplifier is engineered via one‐pot gas diffusion method to attenuate IDH1‐mutated cholangiocarcinoma plasticity and tolerance to ROS therapy, wherein triptolide and IR780 are co‐loaded in DSPE‐mPEG‐modified CaCO3 nanoparticles. Triptolide can blockade Nrf2 to cut off glutathione biosynthesis via blockading proteomic communication, and disrupt redox homeostasis to potentiate IR780‐mediated sonocatalytic ROS production. ROS‐induced mitochondria damages disrupt Ca2+ homeostasis and in turn aggravate ROS accumulation, which cooperates with sonocatalysis and Nrf2 blockade to reprogram mitochondrial energy and substance metabolism (e.g., adenosine triphosphatase and glutathione), hinder DNA self‐repair, and impair IDH1‐mutation‐asired tolerance. Systematic experiments support that these actions in such multichannel sonocatalysis amplifiers indeed disrupt Ca2+/redox homeostasis to disarm robust tumor plasticity and IDH1‐mutation‐induced tolerance to sonocatalysis therapy against IDH1‐mutated cholangiocarcinoma progression. Briefly, the sonocatalysis amplifiers pave a comprehensive avenue to reprogram tumor metabolism, target tumor vulnerability, and attenuate tumor plasticity against genomic instability‐raised treatment adaptation.